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Background
We have previously shown that bortezomib induces a depletion of alloreactive T cells and
allows the expansion of T cells with suppressive properties. In the current study, we analyzed
the potential synergistic effect of bortezomib in conjunction with sirolimus in order to reduce-
graft-versus-host disease without hampering graft-versus-leukemia effect in the allogeneic trans-
plant setting. 
Design and Methods
We evaluated the effect of sirolimus, bortezomib or the combination of both in the prolifera-
tion and activation of in vitro stimulated T lymphocytes. Pathways involved in this synergy
were also analyzed using Western blot assays. Finally, BALB/c mice receiving C57BL/6 allo-
geneic donor bone marrow with splenocytes were used to measure in vivo the effect of this
novel combination on the risk of graft-versus-host disease. 
Results
The combination of both drugs synergistically inhibited both activation and proliferation of
stimulated T cells. Also, the production of Th1 cytokines (IFN γ, IL-2 and TNF) was significant-
ly inhibited. This effect was due, at least in part, to the inhibition of Erk and Akt phosphoryla-
tion. In vivo, the combination reduced the risk of graft-versus-host disease without hampering
graft-versus-leukemia effect, as shown in mice receiving graft-versus-host disease prophylaxis
with sirolimus plus bortezomib being infused with tumor WEHI cells plus C57BL/6 donor BM
and splenocytes.
Conclusions
The current study reveals a synergistic effect of the combination sirolimus and bortezomib to
prevent graft-versus-host disease while maintaining the graft-versus-leukemia effect. 
Key words: allogeneic transplant, sirolimus, bortezomib, graft-versus-host, graft-versus-
leukemia.
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Introduction
Graft-versus-host disease (GVHD) represents a major
challenge and is the main cause of morbidity and mortali-
ty after allogeneic transplantation. Incidence varies greatly
depending on the type of donor and the immune suppres-
sion used to prevent it. Standard GVHD prophylaxis is
currently based on the use of a calcineurin inhibitor plus
methotrexate (MTX). In fact, this combination has been
used for more than 20 years, and remains the standard of
care, although the incidence of acute GVHD is in the range
of 20-40% among patients receiving hematopoietic stem
cells from a matched, related donor, and this is even higher
after unrelated donor transplant.1-3 The incidence of chron-
ic GVHD with the use of a calcineurin inhibitor plus
methotrexate (MTX) after peripheral blood stem cell
transplantation is in the range of 40-70%, and more than
one-third of the patients require immunosuppression for
up to four years after transplant.3,4 These data suggest that
immune tolerance is not obtained in the long term in an
important subset of patients and, in fact, are consistent
with those from in vitro studies showing that calcineurin
inhibitors block the expansion and function of regulatory
T cells (Treg)5-10 which are essential for the generation of a
tolerogeneic immune response. The use of in vivo or in vitro
T-cell depletion significantly reduces the risk of GVHD but
has not led to an improved survival, due to an increase in
the incidence of severe infections and relapses.11,12 For this
reason, new strategies are being evaluated in an attempt to
reduce GVHD without hampering the graft-versus-
leukemia (GVL) effect. 
Sirolimus is the first commercially available inhibitor of
the mammalian target of rapamycin (mTOR). Several
studies and clinical trials have confirmed that sirolimus
allows the risk of GVHD to be reduced after both related
and unrelated donor transplant.13 In addition, an
antileukemic effect has been reported in vitro.14,15
Furthermore, using in vitro assays, several studies have
shown an increase in the number of Tregs after sirolimus
exposure.16-18 Unfortunately, at least using myeloablative
conditioning, the use of sirolimus in combination with cal-
cineurin inhibitors may increase the risk of microangiopa-
thy,19 blocks the development of Treg20 and may subse-
quently compromise tolerance in the long term.21
Bortezomib, a boronic acid dipeptide, is a potent, selec-
tive and reversible inhibitor of proteasome.22 The protea-
some is a multi-enzyme complex present in all cells. It
degrades proteins that regulate cell-cycle progression and
causes proteolysis of the ubiquitinated endogenous
inhibitor of nuclear factor-κB (NF-κB), IκB. The latter
blocks the nuclear translocation and transcriptional activi-
ty of NF-κB.23,24 In normal T lymphocytes, NF-κB translo-
cation to the nucleus only occurs after TCR/CD3 and co-
stimulatory molecule engagement, while it is not activated
in resting T lymphocytes. In our experience, bortezomib
induces selective depletion of alloreactive T cells after a
mixed lymphocyte culture.25 This could prove to be valu-
able in the clinical setting for preventing GVHD, as recent-
ly shown by Koreth et al. in a clinical trial.26 Interestingly,
we have shown that bortezomib does not affect the via-
bility of Treg and allows the expansion of T cells with sup-
pressive properties.27 Accordingly, both sirolimus and
bortezomib could favor the development of a tolerogeneic
immune response after allogeneic transplantation. 
On the basis of these findings, the current study ana-
lyzes the potential synergistic effect of sirolimus together
with bortezomib in the activation pattern of T cells and in
the expansion of Treg. We have evaluated the synergy
between both drugs in a murine model28 in order to pre-
vent GVHD.
Design and Methods
Animals
All animal protocols were approved by the University of
Salamanca Animal Care and Use Committee. Female BALB/c
(H2d) and male C57BL/6 (H2b) mice were purchased from the
Charles River Laboratory, France. Animals were kept in specific
pathogen-free conditions. Mice were between 8 and 12 weeks of
age at the start of the experiments.
Donor mice C57BL/6 were sacrificed by cervical dislocation,
and bone marrow (BM) and spleen were harvested by standard
techniques. Spleen-cell preparations were obtained by gently
crushing the tissues to release the cells. Preparations were filtered
to remove debris and washed twice in PBS for injection. 
BALB/c (H2d) mice were used as recipients in the graft-versus-
host disease (GVHD) model systems. Recipient mice received
total body irradiation (TBI) (850cGy divided in two fractions) from
a Cs source. The control group received irradiation without stem
cell support. Irradiation was followed by the infusion of 5×106
C57BL/6 allogeneic donor BM cells intravenously with or without
splenocytes (5-10×106 cells intravenously) as a source of allogeneic
T cells. Recipient mice then received RPMI, or sirolimus in RPMI
at a dose of 0.25 mg/kg intra-peritoneally on Days 0 to 12 post-
transplant and/or bortezomib at a dose of 1 mg/day intravenously
on Days 0, 1 and 2 post-transplant and/or cyclosporine A at a dose
of 10-15 mg/kg intra-peritoneally on Days 0 to 12 post-transplant.
Mice were monitored and weighed twice a week. All moribund
mice were sacrified according to the standard practice. 
In addition, NOD.CB17-Prkdcscid (NOD/SCID) mice received
bone marrow plus splenocytes from BALB/c mice that had stable
C57BL/6 hematopoiesis and had not developed GVHD after
receiving prior transplantation of BM plus splenocytes and GVHD
prophylaxis with sirolimus and bortezomib. 
Finally, in order to induce leukemia in the mice, 5x104 WEHI 3b
d+ clone 17.3 GFP+ cells (myelo-monocytic leukemic cell line from
a BALB/c background) were infused to BALB/c mice together with
5×106 C57BL/6 BM cells (controls) with or without splenocytes
and sirolimus plus bortezomib as GVHD prophylaxis either after
total body irradiation or on Day 21 after transplantation. 
All experiments were performed at least twice and included 4
animals per group. The degree of systemic GVHD was assessed
by a standard scoring system that incorporates five clinical param-
eters: weight loss, posture (hunching), activity, fur texture, and
skin integrity. Each parameter received a score of 0 (minimum) to
2 (maximum). GVHD score was not blinded. Transplanted mice
were ear-punched, and individual weights were obtained and
recorded on Day 0 and twice a week thereafter. At the time of
analysis, mice from coded cages were evaluated and graded for
each criterion. Acute GVHD was also assessed by detailed
histopathological analysis of skin, liver and intestine.
Chimerism assays were performed in peripheral blood, spleen
and bone marrow at Day 14 day after transplantation. For this pur-
pose, 5 ×105 cells were stained by direct immunofluorescence
using monoclonal antibodies (MoAbs) conjugated with the fol-
lowing fluorochromes: fluorescein isothiocyanate (FITC), phyco-
erythrin (PE); peridin chlorophyll protein-Cyanin 5.5 (PerCP-
Cy5.5) and AlexaFluor. Specific antibodies were purchased from
Becton Dickinson Bioscience (BDB) Pharmingen (San Jose, CA,
T. Caballero-Velázquez et al.
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USA). The following combination was used: anti-H2Db-FITC /
anti-H2Dd-PE / anti-CD45-PerCP-Cy5.5 / anti-CD34-AlexaFluor
or anti-H2Db-FITC / anti-H2Dd-PE / anti-CD45-PerCP-Cy5.5 /
anti-CD3-AlexaFluor. Data were acquired immediately after com-
pletion of sample preparation using a FACSCalibur flow cytome-
ter (BDB) equipped with the CellQuestTM program (BDB).
Results
Effect of sirolimus and bortezomib on T-cell activation,
proliferation and viability
Firstly, we evaluated the effect of sirolimus and then of
bortezomib separately on T-cell activation, proliferation
and viability. Both drugs induced a dose-response inhibi-
tion in T-cell activation and proliferation of T lymphocytes
stimulated with anti-CD3 plus anti-CD28 (Figure 1).
Although the effect of sirolimus was observed at all the
different doses analyzed, the most significant effect was
observed for doses of 50 nM or over both for activation
and proliferation, while viability was affected at doses of
500 nM or over. A dose response to bortezomib was
observed, although its effect on activation and prolifera-
tion was not significant for doses of 100 nM or under,
while viability was greatly affected at doses over 1000
nM. Considering that a concentration of 0.5-5 nM of
sirolimus and of 100 nM of bortezomib did not signifi-
cantly affect any of the parameters analyzed, we chose
these concentrations to evaluate the synergistic effect of
the two drugs. Bortezomib and sirolimus synergistically
inhibited activation as assessed by the expression of CD25
and production of IFNγ, and expression of CD40L and pro-
liferation assessed as expression of PKH (Figure 2).
Calcusyn analysis confirmed a synergistic effect of the
combination for all parameters evaluated (Table 1). These
effects could not be attributed to a decreased viability of T
cells at the concentrations evaluated (Figure 2iv) and were
similar in both CD4+ and CD8+ T cells (Online
Supplementary Figure S1). 
Similar figures were obtained upon adding sirolimus,
bortezomib or both after mixed lymphocyte cultures,
although the percentage of CD25+IFN+ cells was lower
compared to samples stimulated with anti-CD3 plus ant-
CD28; the percentage of CD25+IFN+ cells was 7% (range
4-11%) after MLR while this decreased to 2% (range 0-
3%) in the presence of bortezomib, 2% (range 0-3%) in
the presence of rapamycin at 0.5 nM, and 0.5% (range 0-
1%) upon combining both drugs (P<0.01 when compared
to untreated samples). Similarly to these effects on human
T cells, Online Supplementary Figure S2 shows the effect of
Bz, Sr or both after mixed lymphocyte cultures using T
cells from C57BL6 and BALB/C mice.
Effect of sirolimus and bortezomib on the cytokine
pattern and mechanism involved
We next analyzed the effect of the drugs, either separate-
ly or in combination, on the cytokine pattern of T cells
stimulated with antiCD3 plus antiCD28. The combination
significantly reduced the production of Th1 cytokines
(IFNγ, IL-2 and TNF) as compared to each drug alone while,
as far as Th2 cytokines are concerned, only IL-6 significant-
ly decreased on combining the two drugs (Figure 3). 
In order to explore the mechanisms involved in the
effect of sirolimus and bortezomib, Western blot assays
were performed to identify pathways involved in T-cell
activation and proliferation, such as pAkt and pErk.
Sirolimus at a concentration of 5 nM inhibited the phos-
phorylation of both Akt and Erk while at 100 nM, borte-
zomib did not inhibit phosphorylation either of Akt or of
Erk (Figure 4). Furthermore, an increase in the signal for
both pAkt and pErk was observed after exposure to this
concentration of bortezomib. By contrast, the combina-
tion of the two drugs resulted in a blockade of the activa-
tion of both pathways.
In vivo studies: sirolimus plus bortezomib 
prevents GVHD
In order to confirm the synergistic effect of sirolimus
and bortezomib in vivo, a GVHD mouse model was devel-
oped. Mice received bone marrow (5×106 cells) with or
without 5×106 splenocytes. Additionally, either sirolimus
at a dose of 0.25 mg/kg intra-peritoneally on Days 0 to 12
post-transplant, or bortezomib at a dose of 1 mg/day intra-
venously on Days 0, 1 and 2 post-transplant, or the com-
bination of both drugs was administered to mice receiving
splenocytes. The addition of bortezomib increased sur-
vival as compared to mice receiving bone marrow plus
splenocytes (Figure 5A). Sirolimus further improved sur-
vival while the best results were obtained upon adding
both drugs. Also, signs of GVHD significantly improved in
the group of mice receiving both drugs as compared to
each drug alone (Figure 5B). In order to better determine
the effect of the combination of sirolimus and bortezomib
on survival, a severe GVHD model was established using
10×106 splenocytes. Survival was again significantly better
in the group of mice receiving both drugs, thus confirming
in vivo the results previously shown in vitro (Figure 5A).
Finally, we investigated whether sirolimus had a similar
synergistic effect when used in combination with
cyclosporine A (CsA) at 15 mg/kg on Days 0 to 12 post-
transplant. CsA marginally improved survival relative to
controls, and the combination of sirolimus plus CsA
offered no significant improvement in survival (Figure 5C). 
In vivo studies: graft-versus-leukemia without 
graft-versus-host disease
We also wanted to evaluate whether the immunosup-
pressive effect of the combination was unspecific or, by
contrast, if it allowed the induction of specific immune tol-
erance against the host while maintaining the immune
response against other antigens. To do this, we infused
NOD-SCID mice with 5×106 bone marrow cells plus
5×106 splenocytes from BALB/c mice that had previously
received a transplant from C57BL/6 using GVHD prophy-
laxis with sirolimus and bortezomib and had not devel-
oped GVHD. All these BALB/c mice showed 100%
C57BL/6 hematopoiesis. Interestingly, all NOD-SCID
mice died due to GVHD while, as mentioned above, none
of the donors had previously developed GVHD. Although
further experiments are required to confirm this finding,
these data suggest that the graft had specific immune tol-
erance against BALB/c but was otherwise able to develop
an alloimmune response against histocompatibility anti-
gens from third-party mice. 
To further confirm that the combination of sirolimus
plus bortezomib inhibited GVHD, thereby enabling the
maintenance of the immune response, we infused WEHI
(myelo-monocytic leukemic cells) into BALB/c mice after
total body irradiation. We observed that all BALB/c mice
Sirolimus plus bortezomib prevents GVHD but maintains GVL
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receiving WEHI plus C57BL/6 donor BM cells died due to
leukemic infiltration, while none of those receiving WEHI
cells plus C57BL/6 donor BM cells plus splenocytes and
GVHD prophylaxis with sirolimus and bortezomib devel-
oped leukemic infiltration. Similarly, mice receiving WEHI
cells plus C57BL/6 donor BM cells and GVHD prophylaxis
with sirolimus and bortezomib but without splenocytes
did not develop leukemic infiltration, thus indicating that
the anti-leukemic effect could be attributed to either the
inoculum and / or the drug combination. We, therefore,
exposed WEHI cells to Sr, Bz and the combination of both
drugs; either Bz alone or the combination of both drugs
had a potent direct cytotoxic effect (Online Supplementary
Figure S3). Furthermore, in an attempt to confirm the anti-
leukemic effect of the graft, irrespective of the cytotoxic
effect of the drugs, we infused the leukemic cells on Day
T. Caballero-Velázquez et al.
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Figure 1. (A) Box-plot
showing the dose-depen-
dent effect of sirolimus
on T-cell activation (i,ii)
and proliferation (iii).
Viability (iv) of T cells
only decreased at doses
≥ 500 nM. (B) Box-plot
showing the dose-depen-
dent effect of borte-
zomib on T-cell activa-
tion (i,ii), proliferation
(iii) and viability (iv). Its
effect was not signifi-
cant for doses ≤ 100 nM
for any of the parame-
ters considered. Circles
represent values > 95%
confidence interval and
stars values > 98% CI; 7
cases were analyzed 
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Figure 2. Concentrations
of sirolimus (5 nM) and
bortezomib (100 nM)
were used to evaluate the
synergistic effect of the
two drugs on activation (i,
ii), proliferation (iii) and
viability (iv) of T-cells; 11
cases were analyzed.
Figure 3. CBA cytokine assays in
supernatants after four days of T-
cell culture in the presence of
sirolimus or bortezomib, either sep-
arately or in combination. Box plots
show the effect of the drugs on the
production of Th1 cytokines (A): INF
(i), IL-2 (ii), and TNF (iii). Regarding
Th2 cytokines (B), only IL-6 (iv) sig-
nificantly decreased with the combi-
nation of both drugs; 4 cases were
analyzed.
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21 after transplantation, i.e. nine days after the administra-
tion of sirolimus and, remarkably, none of the mice that
received splenocytes on Day 0 developed either GVHD or
leukemic infiltration. This is in contrast to mice receiving
WEHI cells on Day 21 after Sr and Bz without having
received splenocytes on Day 0 since, in this subgroup, all
mice developed leukemic infiltration (n > 8 for all experi-
ments described). Therefore, this approach enabled us to
separate the GVHD and GVL effects (Online Supplementary
Figure S4).
Discussion
The combination of MTX plus calcineurin inhibitors has
been widely used since the early pre-clinical studies con-
ducted in the 1980s29,30 and it is still considered the gold
standard for GVHD prophylaxis. Nevertheless, this com-
bination is far from ideal. It induces numerous side effects,
must be maintained for long periods and, most important-
ly, is not effective in a significant number of patients who
ultimately develop GVHD. Attempts to improve this
approach have had mixed results.31,32 Strategies based on in
vitro or in vivo T-cell depletion have enabled the risk of
GVHD to be reduced but have not improved survival
because of an increased risk of relapse and severe infec-
tions. Therefore, strategies that could reduce the incidence
of GVHD without hampering GVL are urgently required. 
Other drugs have emerged, such as sirolimus, that have
yielded promising results in vitro and in vivo. Indeed, several
studies have shown that sirolimus expands regulatory or
suppressive T cells in vitro16,17 which could induce tolerance
after allogeneic transplantation. On the other hand, clini-
cal trials13 have reported improved overall survival in
patients receiving sirolimus plus tacrolimus, although a
significant proportion of patients still develop GVHD.
One of the major problems with sirolimus is its toxicity
profile in combination with calcineurin inhibitors, includ-
ing the development of microangiopathy or veno-occlu-
sive disease, especially among patients receiving myeloab-
lative conditionings.33,34
We have previously reported that bortezomib induces
selective depletion of alloreactive T cells,25 while Treg are
resistant to this pro-apoptotic effect. Furthermore, borte-
zomib allows the expansion of a suppressive T-cell sub-
population in vitro.27 In this context, and bearing in mind
that sirolimus and bortezomib target different pathways
that could synergistically affect T-cell function, in the cur-
rent study we combined both drugs and confirmed the
existence of a very potent synergistic effect in terms of
inhibition of both activation and proliferation of T cells.
This is not due to increased apoptosis but to a genuine
immune-modulatory effect when the two drugs are used
in combination, as shown by the effect on the cytokine
secretion pattern of stimulated T cells. Interestingly, Th1
cytokines were strongly affected by the combination
while Th2 cytokines, with the exception of IL-6, were pre-
served. This combination may also inhibit the chronic
active antibody-mediated rejection that occurs in experi-
mental renal transplantation in the rat35 and could suppress
activation of rapamycin-resistant memory T-cells.36 The
current study not only confirms the synergy of sirolimus
plus bortezomib in a fully mismatched hematopoietic
stem cell transplant model, but also shows that it yields
better results than those observed with the classical com-
bination of sirolimus plus calcineurin inhibitors which is
currently used in the clinical setting. In fact, data from the
current study suggest that CsA might inhibit the protec-
tive effect of sirolimus. This could be attributed to either
the toxicity of the combination or to the effect of CsA
abrogating the expansion of Tregs. This is in contrast to
the combination with bortezomib since, as previously
reported, both drugs allow the expansion of Tregs. In the
current study, we failed to demonstrate an increase in the
number of Tregs during the first 50 days postransplant
(data not shown). Further studies will be performed to con-
firm these data with a longer follow up but, most impor-
tantly, we confirmed that this strategy enabled GVHD to
be avoided in the host maintaining the graft-versus-tumor
effect that led to an improvement in survival using
sirolimus plus bortezomib. Remarkably, the antitumor
Table 1. Summary of the activity (fraction affected (Fa)) and combination
indexes (CI) of several doses of bortezomib and sirolimus or combinations of
both drugs as analyzed by CalcuSyn software.
Concentration (nM) %CD25+IFN+ %CD40L PKH 
Bz Sr Fa CI Fa CI Fa CI
1 0.0570 0.0165 0.0165
10 0.1547 0.1465 0.1465
100 0.4352 0.1758 0.1758
1000 0.9514 0.6459 0.6459
10000 0.9710 0.8294 0.8294
0.5 0.3647 0.6589 0.6589
5 0.5176 0.6517 0.6517
50 0.9741 0.9734 0.9734
500 0.9949 0.9810 0.9810
100 0.5 0.7294 0.529 0.7983 0.158 0.7983 0.158
100 5 0.8858 0.440 0.877 0.495 0.877 0.495
1000 5 0.9827 0.111 0.9632 0.055 0.9632 0.55 Figure 4. Western blot assays for pAkt and pErk in Jurkat T cells
stimulated with anti-CD3 plus anti-CD28 (i) untreated, or treated
with (ii) sirolimus 5nM, (iii) bortezomib 100 nM and (iv) sirolimus 5
nM plus bortezomib 100 nM. The numbers shown below the bands
indicate the quantitative measurement of the fold change with
respect to the untreated sample; data from 4 experiments are
shown.
i ii iii iv
i ii iii iv
1 0.93 1.28 1.02Fold:
Fold:
pAkt
pErk
tubulin
tubulin
1 0.93 1.28 1.02
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effect was due to both a direct cytotoxic effect of the
drugs on the tumor cells and to a GVL effect of the inocu-
lum. This double mechanism is of great interest in the clin-
ical setting since it would avoid relapses early after trans-
plant until the immune response is fully developed.
Furthermore, previous studies have suggested that Bz
increases the expression of NK activation receptor ligands
in target cells that might also contribute to maintain or
even increase the GVL effect without increasing
GVHD.37,38
In order to explore the pathways that might account for
this synergy, we observed that at doses of 5 nM of
Sirolimus plus bortezomib prevents GVHD but maintains GVL
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Figure 5. GVHD mouse model. (A) Kaplan-Meier curves repre-
senting overall survival of mice after a dose of 5x106 (i) or
10x106 splenocytes (ii) treated with or without sirolimus at a
dose of 0.25 mg/kg, intraperitoneally, for 14 days, bortezomib
at a dose of 1 mg intravenously on Days 0, +1, +2  post-trans-
plant, or the combination of the two drugs. Control groups
receiving only splenocytes without any additional drug to pre-
vent GVHD (so called “GVHD” group), or receiving irradiation
without stem cell support (“TBI” group) are shown. Control
mice receiving BM without splenocytes survived until the end
of the experiment. (B) Evolution of weight loss up to Day 21 (i)
or up to Day 42 after transplant (ii), hunching (iii), activity (iv),
fur texture (v) and skin integrity (vi) among mice receiving a
dose of 5x106 splenocytes, with or without the drugs. GvHD
score was not blind. (C) Kaplan-Meier curves representing overall survival in mice receiving a dose of 5x106 splenocytes, with or without
sirolimus, cyclosporine or their combinations. The group receiving only sirolimus had the best outcome, so no beneficial effect was observed
upon using the combination. The group of mice receiving BM without splenocytes survived until the end of the experiment (> 60 days post-
infusion). Five mice per group were included in each experiment. Data from at least 2 experiments are shown.
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sirolimus and 100 nM of bortezomib, the former inhibited
Erk and Akt phosphorylation while this effect was not
observed for bortezomib. Furthermore, after exposure to
100 nM of bortezomib, the phosphorylation of both sub-
strates was slightly increased. It has previously been
reported that the increased expression of pAkt in tumor
cell lines could favor resistance to the pro-apoptotic effect
of proteosome inhibitors.39 Remarkably, the concomitant
use of sirolimus avoids the activation of these pathways in
Jurkat T cells. Considering previous studies showing that
both in vitro25,27 and in clinical models26 bortezomib signifi-
cantly decreases the risk of GVHD, the data in the current
study on Akt and Erk phosphorylation are remarkable
since we demonstrate that the addition of sirolimus blocks
pathways the activation of which might allow T cells to
escape from the inhibitory effect of Bz on activation and
viability of T lymphocytes.
In conclusion, the current study reveals the existence of a
potent synergistic effect between sirolimus and bortezomib
in terms of inhibition of T-cell activation and proliferation,
with a marked decrease in the secretion of Th1 cytokines.
These effects are at least partly mediated by the blockade of
the Akt and Erk pathways. Finally, this combination
allowed GVHD to be prevented while maintaining the GVL
effect. On the basis of these findings, a clinical trial using
sirolimus plus bortezomib post-transplant is planned.
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